- Home
- JAZZ vs KEP Comparison
JAZZ vs KEP Comparison
Compare JAZZ & KEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JAZZ | KEP |
|---|---|---|
| Founded | 2003 | 1961 |
| Country | Ireland | South Korea |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.1B | 14.5B |
| IPO Year | 2007 | 1996 |
Fundamental Metrics
Financial Performance| Metric | JAZZ | KEP |
|---|---|---|
| Price | $208.12 | $10.69 |
| Analyst Decision | Buy | |
| Analyst Count | 22 | 0 |
| Target Price | ★ $294.64 | N/A |
| AVG Volume (30 Days) | 715.2K | ★ 719.4K |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | N/A | ★ 3.90% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.17 | N/A |
| Revenue | ★ $1,618,693,000.00 | N/A |
| Revenue This Year | $10.65 | $0.33 |
| Revenue Next Year | $5.76 | $1.57 |
| P/E Ratio | $29.35 | ★ $4.54 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $128.80 | $10.43 |
| 52 Week High | $266.38 | $23.41 |
Technical Indicators
Market Signals| Indicator | JAZZ | KEP |
|---|---|---|
| Relative Strength Index (RSI) | 26.18 | 40.03 |
| Support Level | $194.77 | N/A |
| Resistance Level | $241.39 | $12.74 |
| Average True Range (ATR) | 6.94 | 0.18 |
| MACD | -1.78 | -0.02 |
| Stochastic Oscillator | 4.51 | 23.61 |
Price Performance
Historical ComparisonAbout JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About KEP Korea Electric Power Corporation
Korea Electric Power Corp is an electric utility company in which the government of South Korea holds a controlling stake. The firm operates in the following segments: Transmission and distribution, Electric power generation (Nuclear), Electric power generation (Non-Nuclear), Plant maintenance & engineering service, and Others. The majority of the energy produced by the company comes from its nuclear and coal-fired assets. Korea Electric Power generates revenue through the Transmission and distribution segment. Geographically, it derives maximum revenue from Domestic operations.